Why the study?
Does ketoconazole combined with doxorubicin improve PSA response in patients with androgen-independent prostate cancer?
Does ketoconazole combined with doxorubicin improve PSA response in patients with androgen-independent prostate cancer?
Ketoconazole combined with doxorubicin shows a 55% PSA response rate in androgen-independent prostate cancer but causes frequent adrenal insufficiency and potential cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Supports PSA responses in androgen-independent prostate cancer; leaves open clinical use pending randomized trials and toxicity data.
Sella et al. (1994) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: